Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

László Gulácsi (), Fanni Rencz, Márta Péntek, Valentin Brodszky, Ruth Lopert, Noémi V. Hevér and Petra Baji
Additional contact information
László Gulácsi: Corvinus University of Budapest
Fanni Rencz: Corvinus University of Budapest
Márta Péntek: Corvinus University of Budapest
Ruth Lopert: George Washington University
Noémi V. Hevér: Corvinus University of Budapest
Petra Baji: Corvinus University of Budapest

The European Journal of Health Economics, 2014, vol. 15, issue 1, No 4, 27-34

Abstract: Abstract Background Several Central and Eastern European (CEE) countries require cost-utility analyses (CUAs) to support reimbursement formulary listing. However, CUAs informed by local evidence are often unavailable, and the cost-effectiveness of the several currently reimbursed biologicals is unclear. Aim To estimate the cost-effectiveness as multiples of per capita GDP/quality adjusted life years (QALY) of four biologicals (infliximab, etanercept, adalimumab, golimumab) currently reimbursed in six CEE countries in six inflammatory rheumatoid and bowel disease conditions. Methods Systematic literature review of published cost-utility analyses in the selected conditions, using the United Kingdom (UK) as reference country and with study selection criteria set to optimize the transfer of results to the CEEs. Prices in each CEE country were pro-rated against UK prices using purchasing power parity (PPP)-adjusted per capita GDP, and local GDP per capita/QALY ratios estimated. Results Central and Eastern European countries list prices were 144–333 % higher than pro rata prices. Out of 85 CUAs identified by previous systematic literature reviews, 15 were selected as a convenience sample for estimating the cost-effectiveness of biologicals in the CEE countries in terms of per capita GDP/QALY. Per capita GDP/QALY values varied from 0.42 to 6.4 across countries and conditions (Bulgaria: 0.97–6.38; Czech Republic: 0.42–2.76; Hungary: 0.54–3.54; Poland: 0.59–3.90; Romania: 0.77–5.07; Slovakia: 0.55–3.61). Conclusion While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data.

Keywords: Cost-utility; Inflammatory conditions; Biologicals; Central and Eastern Europe; HTA; Reimbursement (search for similar items in EconPapers)
JEL-codes: I (search for similar items in EconPapers)
Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-014-0591-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
Journal Article: Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries (2014)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:15:y:2014:i:1:d:10.1007_s10198-014-0591-7

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-014-0591-7

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().